|
ACT Biotech Acquires Clinical and Early Stage Oncology Portfolio Licenses from Bayer Healthcare
08 May 2008
ACT Biotech acquires an anti-angiogenic receptor tyrosine kinase inhibitor entering Phase II clinical studies for colorectal cancer.
|
|
|
|
Dalton Pharma Services Licenses Thermo Fisher Scientific Enter Drug Development Agreement
07 May 2008
Dalton will use a proprietary Thermo Fisher manufacturing process to produce nucleic-acid biopolymers for pharmaceutical use.
|
|
|
|
DiaKine Therapeutics and Kinexum Metabolics to Develop Combination Treatment to Type 1 Diabetes
07 May 2008
DiaKine’s Lisofylline and Kinexum’s INGAP peptide combo therapy is set for Phase 2 clinical trial.
|
|
|
|
GE Healthcare Signs Global Molecular Diagnostic Agreement to Advance Respiratory Drug Development
06 May 2008
Merck will be granted access to Spin Signal Technology™ to provide high speed, quantitative imaging of the lung using Magnetic Resonance Imaging.
|
|
|
|
Targacept Announces Designation of Lead Compound in Smoking Cessation Program
06 May 2008
The designation triggers milestone payment of $500,000 from GlaxoSmithKline.
|
|
|
|
Galapagos and Allergan Enter Drug Discovery Collaboration
06 May 2008
Galapagos' service division, BioFocus DPI, will provide assay development and high-throughput screening services for several Allergan targets.
|
|
|
|
Caliper LS and DiscoveRx Collaborate to Offer Solutions for Cell-Based GPCR Profiling and Lead Optimization
06 May 2008
The combined offering bundles Caliper LabChip systems with DiscoveRx’s cellular assays, including PathHunter™ B Arrestin and cAMP Hunter™.
|
|
|
|
Malvern Instruments Presentation Shows Power of Near-infrared Chemical Imaging in Quality by Design
05 May 2008
The presentation highlights, how SyNIRgi NIR-CI system can provide the data and product understanding required for Quality by Design.
|
|
|
|
Syndexa Pharmaceuticals Corporation and ChemDiv Announce Discovery Collaboration
02 May 2008
ChemDiv will discover small molecule ligands for biotargets nominated by Syndexa.
|
|
|
|
GlaxoSmithKline Uses Clinical Graphics Solution Developed by Insightful Corporation
30 April 2008
GSK using Insightful’s clinical graphics solution for communicating safety and efficacy information in clinical data.
|
|
|
|
BioSeek Initiates Research Collaboration with Lexicon Pharmaceuticals
30 April 2008
BioSeek’s BioMAP® Systems will be used to help further evaluate selected compounds associated with several of Lexicon’s drug discovery programs.
|
|
|
|
PerkinElmer Announces new Subsidiary to Distribute and Service Instrumentation in Ireland
30 April 2008
New subsidiary will assume direct responsibility for instrumentation sales, service and support for customers in Ireland.
|
|
|
|
Thermo Fisher Scientific Extends Latin America Network with new Chilean Partner for Informatics
30 April 2008
Alta Tecnologia will support sales activities in Chile, Paraguay, Uruguay and Bolivia for the Thermo Scientific portfolio of informatics products.
|
|
|
|
Acusphere Submits new Drug Application for FDA Approval of Imagify™
29 April 2008
The NDA includes data from studies of Imagify in more than 1,000 patients worldwide, including two pivotal international multi-center Phase III clinical trials.
|
|
|
|
MorphoSys Announces Completion of First Dosing in Phase 1 Trial for MOR103 Program
28 April 2008
The safety review of the medical data from the lowest dosing group yielded a determination that it was safe to proceed with the second dosing group.
|
|
|
|
CMD Bioscience and Research Foundation of SUNY on Behalf of Stony Brook University Sign Exclusive Licensing Agreement
28 April 2008
The deal gives CMD Bioscience exclusive control of a computational method for predicting protein-protein and protein-peptide binding affinities.
|
|
|
|
Metabasis Therapeutics Extends Collaboration with Merck to Develop AMPK Activators for Diabetes and Other Metabolic Diseases
24 April 2008
The two companies will continue their joint efforts to identify small molecule therapeutics with the potential to treat type 2 diabetes and other metabolic diseases.
|
|
|
|
New Fragment-based Drug Discovery Platform Announced between IOTA and Beactica
24 April 2008
Both companies will join forces to deploy a proprietary FBDD-based lead discovery and optimization platform.
|
|
|
|
Calando Receives FDA Approval for Phase I Clinical Trial Using a Targeted siRNA Nanoparticle Therapeutic
22 April 2008
FDA approval to proceed with proprietary RONDEL™ drug delivery system and siRNA combined for first targeted, systemic delivery in oncology phase I clinical trial.
|
|
|
|
Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
22 April 2008
SBI-087 for RA builds on Trubion and Wyeth's clinical experience with Trubion's lead compound, TRU-015, and is based on Trubion's SMIP™ technology.
|
|
|
|
Aida Announces new Anti-Cancer Drug Under Development
21 April 2008
Company believes that the integration of Vasostatin-Apo2L, its pre-clinical product, will have higher efficacy in certain cancer treatments than currently prescribed methods.
|
|
|
|
Insert Therapeutics to Initiate a Multinational Phase II Clinical Trial of Lead Drug Candidate IT-101
18 April 2008
Company has filed with the U.S. FDA to initiate the trial evaluating the safety and efficacy of its drug candidate in patients with ovarian cancer.
|
|
|
|
Galapagos Licenses Clinical Rheumatoid Arthritis Program
18 April 2008
Galapagos announces the in-licensing of Nanocort®, a patented liposome-formulation of prednisolone to treat inflammatory diseases, from Enceladus Pharmaceuticals.
|
|
|
|
ACD/Labs Announces an Important Investment by Sanofi-Aventis for Production Facilities in Europe
18 April 2008
Sanofi-Aventis deploys ACD/Labs’ suite of NMR tools at five of its production facilities in France, Germany, and Hungary.
|
|
|
|
Intellection and Bruker AXS Sign Strategic Collaboration Agreement
18 April 2008
Intellection to expand its range of products and services, directly supplying X-ray fluorescence and X-ray diffraction systems from Bruker AXS to its customers.
|
|
|
|
University of Colorado Opens Lab Focused on Detecting, Treating Pharmaceuticals in Water
17 April 2008
Agilent to provide core liquid chromatograph/mass spectrometer (LC/MS) instrumentation for the lab.
|
|
|
|
Ingenuity Systems and Pfizer Announce Strategic Partnership for Pathway Analysis
17 April 2008
Ingenuity Pathways Analysis to be deployed broadly to researchers at Pfizer, integrated with internal solutions.
|
|
|
|
SuperGen's DNA Methyltransferase Inhibitor, S-110, Improves In-vivo Efficacy Profile of Decitabine
15 April 2008
Company claims that its DNA methyltransferase inhibitor restored sensitivity to cisplatin observed in ovarian carcinoma xenografts.
|
|
|